|
|
 |
| |
|
Home > Drug Companies > Mylan Pharmaceuticals, Inc.
Mylan Pharmaceuticals, Inc.
The mission of Mylan Pharmaceutical, Inc., an ASTA Medica company, is to build a major prescription medical company through the research, development, and marketing of novel products and compounds particularly in the areas of respiratory medicine, allergy, and pain.
Mylan Pharmaceuticals plays an increasingly important role in their healthcare system by making safe and effective prescription drugs more affordable for millions of Americans. Last year, pharmacists filled more than 197 million prescriptions with products from Mylan, making it the 1 US based manufacturer of generic pharmaceutical products.
Founded in a small town in West Virginia, Mylan was one of the first pharmaceutical companies in the United States to develop more affordable alternatives to name brand prescription drugs. Today, Mylan manufactures products for diseases ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease, and schizophrenia to sleep disorders, to name just a few.
Drug products sold in the United States are approved by the Food and Drug Association whether they are brand name or generic. Most people believe that if something costs more, it has to be better quality. In the case of generic drugs, this is not true, says Gary Buehler, Director of Food and Drug Associations Office of Generic Drugs.
The Mylan Institute of Pharmacy was developed with the pharmacist and pharmacy student in mind. All continuing education programs sponsored by The Mylan Institute of Pharmacy are developed by providers approved by the American Council on Pharmaceutical Education. Continuing education credits will then be issued to all qualified participants.
Their vision is to lead the way to a healthier world. By carrying out this vision at every level of their organization, they will be recognized by their employees, customers and shareholders as the best pharmaceutical company in the world, resulting in value.
Back to Drug Companies
|
|
|
|
|
|
|
|